Curis expands emavusertib PCNSL response pool as TakeAim CLL enrolment accelerates
Curis reports updated emavusertib responses in PCNSL and faster CLL enrolment, while durability, safety and funding remain critical tests.
Pharma & Biotech
Pharma & Biotech
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Pharma & Biotech
Is Eli Lilly’s Jaypirca now the most compelling single-agent therapy in untreated CLL?
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.
Pharma & Biotech
Eli Lilly targets first-line CLL with Jaypirca as BRUIN CLL-314 trends toward PFS benefit
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?